Vendor status logFDA letter
Peptide Partners: status log
Site responding; FDA warning letter Aug 24 2026
Domains: peptide.partners · Last checked 2026-10-19 · Reviewed by Amino Wire Editorial Team
Summary
FDA reviewed peptide.partners in July 2026 and, in a warning letter dated August 24, 2026 to Peptide Partners LLC of Sarasota, Florida, called seven products unapproved new drugs, including its reconstitution solution (bacteriostatic water).
Dated facts
1 entries · newest first-
FDA warning letter
FDA warning letter 735063: “GLP-1 S (Semaglutide),” “GLP-2 T (Tirzepatide),” “GLP-3 Reta (Retatrutide),” “SS-31 (Elamipretide),” “Tesa Peptide (Tesamorelin),” “PT-141 (Bremelanotide)” and “Reconstitution Solution (BAC)” called unapproved new drugs. Response requested within 15 business days.
Our site checks
automated · single location| Checked (UTC) | URL | HTTP | What loaded |
|---|---|---|---|
| 2026-10-19 06:18:00 | https://peptide.partners/ | 200 | HTTP 200; title “Peptide Partners | Tested & Verified Pure Peptides”. Add-to-cart markup was not detected in the static HTML; we did not test further. |
A page loading does not show that a business is lawful, that orders are fulfilled, or anything about product quality. We did not place orders.
Notes and unknowns
- FDA's site does not show a response or close-out letter as of our check.